-
What were the big game changers for 2024?
November 9, 2024Chaired by Prof. Axel Merseburger (DE), Dr. Alison Tree (GB) and Prof. Jan Oldenburg (NO), the game-changing session on...
00 -
Stepping into their shoes: EU-ProPER studies partners of PCa patients
November 8, 2024What is the extent of the physical and psychological burdens that prostate cancer (PCa) imposes on the partners of...
-
Integrating AI for PCa screening and diagnosis: ProCancer-I
November 7, 2024During the first session by the EAU Section on Urological Imaging on Day 1 at EMUC24 in Lisbon, biomedical...
-
2023 ends with big game changers for GU cancers
November 4, 2023Chaired by Prof. Axel Merseburger (DE), Prof. Karim Fizazi (FR) and Prof. Valerie Fonteyne (BE), the game-changing session on...
-
“If you can’t measure it, you can’t improve it”
November 3, 2023Day two of EMUC23 introduced and implemented the morbidity and mortality (M&M) meeting format during the aptly-titled Plenary Session...
-
EMUC23 tackles current challenges of PSMA PET/CT in PCa
November 2, 2023Plenary Session 5 “Nuclear medicine in urology: Lessons learnt and new horizons” of the EAU Section of Urological Imaging (ESUI)...
-
ESUI: Getting ready for the new EU approach to PCa screening
November 2, 2023This year, the annual EAU Section of Urological Imaging (ESUI) meeting has been integrated into the 15th European Multidisciplinary...
-
Diagnosing PCa – what’s the best option?
November 11, 2022The objective of the 14th European Multidisciplinary Congress on Urological Cancers is to work together to achieve the best...
-
EMUC22: Relevant topics and Prof. Stenzl’s personal highlights
June 27, 2022Year after year since 2008, the European Multidisciplinary Congress on Urological Cancers (EMUC) provides the urological community with integrative...
-
Personalised approaches to treating GU cancers
November 27, 2021Personalised approaches such as the use of circulating tumour DNA (ctDNA) biomarkers and genetic testing is the way to...
